Progress in Haemostasis

Johanna A. Kremer Hovinga; Rüdiger E. Scharf

doi:10.1055/s-0037-1619830

Hämostaseologie, Table of Contents

Hamostaseologie 2017; 37(01): 9-11
DOI: 10.1055/s-0037-1619830

Editorial

Schattauer GmbH

Progress in Haemostasis

From individual patients to pathophysiological insightsFortschritte in der HämostaseologieVon individuellen Patienten zu pathophysiologischen Einblicken

Johanna A. Kremer Hovinga

¹Department of Hematology & Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland

²Department of Clinical Research, University of Bern, Bern, Switzerland

,

Rüdiger E. Scharf

³Division of Hemostasis, Hemotherapy & Transfusion Medicine, and Hemophilia Comprehensive Care Center, Heinrich Heine University Medical Center, Düsseldorf, Germany

⁴Biological Medical Research Center, Heinrich Heine University, Düsseldorf, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Scharf RE, Kemkes-Matthes B. Hämostaseologie – Progress in Haemostasis. GTH is moving to a European society. Hämostaseologie 2016; 36: 5-6.
2 Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol 1964; 23: 101-112.
3 Mourik M, Eikenboom J. Lifecycle of Weibel-Palade bodies. Hämostaseologie 2017; 37: 15-26.
4 Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hämostaseologie 2017; 37: 27-37.
5 Kühne T. Diagnosis and management of immune thrombocytopenia in childhood. Hämostaseologie 2017; 37: 38-46.
6 Haas SA, Dettmer V, Cathomen T. Therapeutic genome editing with engineered nucleases. Hämostaseologie 2017; 37: 47-54.
7 Scharf RE. Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. What and how can we do better? Hämostaseologie 2016; 36: 195-198.
8 Berntorp E. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?. Hämostaseologie 2017; 37: 55-59.
9 Brehm MA. Von Willebrand factor processing. Hämostaseologie 2017; 37: 61-74.